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The struggle to identify susceptibility genes for complex disorders has stimulated geneticists to develop new
approaches. One approach that has gained considerable interest is to focus on genetically isolated
populations rather than on the general population. There remains much controversy and theoretical debate
over the feasibility and advantages of such populations, but recent results speak in favor of the feasibility of
this approach, and will be reviewed here.
In July 2003, the complete sequence of the human genome is
expected to be finished, but already over the past few years the
progress of the Human Genome Project has dramatically
changed the daily live of human geneticists. Gene finding for
disorders with Mendelian inheritance is rapidly shifting from
cumbersome positional cloning projects requiring many years to
complete (e.g. with Huntington’s disease) (1) to positional
candidate gene approaches using in silico candidate gene
selection (e.g. hemochromatosis) (2). Although for the large
majority of our estimated 32 000 genes the biological function is
still largely unknown, we have now at least acquired knowledge
of their existence and localization within our genome.
The expectations on the tradeoffs of the Human Genome
Project have also resulted in a shift of attention of scientists
towards gene finding for more complex disorders. This is often
accompanied by statements that all interesting Mendelian
disorders have been, or soon will be, mapped. This statement
neglects the current status of human disease mapping.
In the Online Mendelian Inheritance of Man (OMIM) (http://
www3.ncbi.nlm.nih.gov/omim/), >10 000 disease entries are
listed, but for only 10% have the responsible genes been
identified (http://www.ncbi.nlm.nih.gov/locuslink/).
The importance of the continuation of mapping Mendelian
disorders is demonstrated by our increased understanding of
many biological processes through studying the pathogenesis
of rare disorders such as mental retardation (3). Especially
instrumental have been those diseases in which genes
responsible for rare familial forms have been identified and
have helped our understanding of the pathways involved in the
more common and complex forms of diseases. An example is
neurodegenerative disorders, where common pathways are
being unraveled using Mendelian forms of the disease (4–6).
COMPLEX DISEASE
In Mendelian disorders, mutations are in general directly
causal, and segregation of phenotypes can be followed in
families, allowing family-based linkage approaches. For com-
plex disorders, genetic influences are less clear cut, and so far
the progress in gene identification for these disorders has been
disappointing. Very few genetic risk factors with convincing
evidence have been identified. The most widely used examples
for successful identification of risk factors for complex
disorders are apolipoprotein E for Alzheimer’s disease (7,8)
and factor V Leiden clotting factor for thrombophilia (9,10).
The main reason for this very limited success is that it is
simply not known how the genetics of complex disorders
should be described or modeled (11). Approaches that have
been so successfully used for Mendelian disorders were
originally designed for use with well-defined genetic para-
meters. However, complex disorders do not clearly follow
Mendelian laws of inheritance because of complicating factors
such as phenocopies, genetic heterogeneity, variable clinical
expression, age at onset, new mutations, incomplete pene-
trance, polygenic inheritance and environmental risks. Only a
combination of these genetic and (often) environmental risk
factors leads to the presentation of the phenotype; for genetic
risk factors with small effects, classical linkage analysis using
independent pedigrees therefore has very limited power to
detect a locus.
The extent to which genetic risk factors contribute to the
onset of common diseases is largely unknown. Widely used
measures for heritability and relative attributable risk not only
measure the effect of all genetic risk factors combined, but also
include the effects of shared environmental risk factors and the
interactions between these risk factors. Since these measures
pool together the effects of all genetic risk factors, it is not clear
how many and how strong the individual risk factors are (12).
There are two main hypotheses for explaining the genetics of
complex disorders. Firstly, in the multi-equivalent risk model,
many rare variants exist in the population with varying effect
on risk (each variant being a strong risk factor). Secondly, in the
restricted polymorphism model, a relatively small pool of com-
mon disease alleles exists (each factor being a weak risk factor).
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These risk factors can be both genetic and environmental, and
can increase or decrease the risk for disease. It is likely that
both these and intermediate (oligogenic) situations exist—as
for diabetes, where interactions between environmental and
genetic risk factors are well documented. For example, the
effect of changes towards a more Westernized life style by Pima
Indians and Japanese is associated with genetic susceptibility to
the disease (13–15). And susceptibility in the NOD mouse
model can be explained by several factors, with only a few
having a strong effect (16). Other disorders with oligogenic
inheritance are Hirschprung’s disease (17,18) and late-onset
Alzheimer’s disease (19–21).
ALTERNATIVE METHODS FOR GENE FINDING
The use of alternative linkage approaches such as affected
sib-pair analysis circumvents some of the problems associated
with linkage analysis on larger families by avoiding extensive
modeling of the genetic parameters. Other researchers have
looked for more direct approaches to circumvent genetic
modeling by directly testing the effect of sequence variations in
candidate genes using cases versus controls in association
studies on genes that are predicted to harbor risk factors
because of their known biological function. In its basic design,
this approach is very appealing if the function of the candidate
gene is fully known. Because of the progress in our under-
standing of the function of many genes, this approach is
becoming more and more feasible. However, at this point for
most genes we still have very limited knowledge, and therefore
candidate genes are often put forward with very few arguments
supporting their biological role in a disease process. This is
reflected in the very small number of genetic association
studies that have actually been replicated and accepted in the
scientific community. The association of the E4 allele of
apolipoprotein E is often used as an example of the successful
identification of a genetic risk factor for Alzheimer’s disease by
association studies, but this risk factor was originally localized
by linkage analysis (7,8). Another approach that holds great
promise is to look at quantitative traits associated with disease
that might segregate as more Mendelian traits—thus to
subdivide patient populations or to use congenic animal
models (22,23).
LINKAGE VERSUS ASSOCIATION
A comparison of the statistical power of linkage-based
approaches versus association studies strongly favored the
latter over linkage-based approaches such as sib-pair studies,
especially for mild risk factors with a genotype risk ratio g< 4
(24,25). For risk factors with g 2, unrealistic sample sizes for
linkage studies (2500 families) would be required. It should
be realized that the measure for describing a risk factor g is
different from the more commonly used sibling recurrence risk
ratio l (26); g¼ 2 correspondents to l¼ 1.3. Linkage studies
for risk factors of l 2 are certainly feasible, although we
should be aware that we consider the l for the specific risk
factor under investigation and not for the disease as a whole
(27). Another important observation is that it was assumed in
the calculations that the tested markers were in complete
linkage disequilibrium with the biologically relevant risk factor
within the whole population (28). Linkage disequilibrium (LD)
refers to the non-random association of marker alleles within a
genomic region in which the presence of an allele of one
marker predicts the presence of an allele of a nearby marker.
LD is eroded by recombination and gene conversion (Fig. 1).
Thus the predictions above are only true if there has been a
single mutation event in the gene under study. Otherwise, no
LD will be detected. Given the experience with allelic
heterogeneity in many Mendelian disorders, this is an unlikely
situation. In contrast, linkage can be detected even if multiple
mutation events have occurred, and therefore genome-wide LD
mapping in population samples potentially has high power to
detect such genes, but it is restricted by the amount of allelic
heterogeneity.
Risch and Merikangas (24) recognized that as part of the
Human Genome Project large numbers of single-nucleotide
polymorphisms (SNPs) would become available and that
these SNPs could serve as an excellent tool for genome-wide
association studies. This recognition caused considerable
debate on how many SNPs would then be needed for
genome-wide association studies and how genome-wide
significance could be achieved if hundreds of thousands of
SNPs had to be tested.
SIGNAL-TO-NOISE RATIO
In general, the statistical power to detect a real association or
linkage is limited by the background noise in the population
under study. This noise consists of all possible combinations of
environmental and genetic factors present in the population.
Therefore, in heterogeneous populations, large sample sizes
would be needed to obtain sufficient statistical power to detect
genetic risk factors. More homogeneous populations such as
genetically isolated populations have been proposed as a
possible alternative for these large sample sizes, because
environmental variation might be lower and the genetic make-
up of these populations is expected to be less complex owing
to founder effects, thus improving the signal-to-noise ratio.
The use of genetically isolated populations is not new; for
example, in Finland, there are numerous examples of
Mendelian disorders with increased prevalence (29). This has
been especially valuable for mapping rare recessive disorders,
but many researchers believe this could be a solution for more
complex disorders as well because of the relatively uniform
genetic background of the population. Some culturally and
genetically isolated populations have a more similar way of
living, eating habits and natural environment that reduces
environmental variation. Often these populations have been
founded by a small number of individuals, followed by a period
of genetic isolation, during which genetic drift might have been
seen and population expansion mainly occurred by population
growth and not by immigration. In addition, if genealogical
records are available, the kinship coefficient of patients can be
determined, which is often higher than in heterogeneous
populations. In countries from Scandinavia, for example, state
healthcare registries have been maintained over centuries (30).
Increased kinship should also be suitable for detecting
recessive effects of common risk factors.
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Each genetically isolated population has its own demographic
history, and each might have its own advantages and
disadvantages. Very old isolates (>100 generations) with
limited population growth such as the Saami in northern
Scandinavia are carrying very old (general) mutations or new
(population-specific) mutations. Because of the prolonged
period of isolation, considerable genetic drift has occurred.
For mapping disease genes in these populations, in general,
short regions of LD are expected because many meiotic events
have occurred in founder chromosomes. However, if consider-
able consanguinity in such populations exists and only a
limited number of founder chromosomes were present, it might
be difficult to distinguish disease-associated haplotypes from
the background haplotypes.
In younger isolates (100 generations) such as exist in
Finland (early and late settlement), Iceland, Sardinia and Japan
with low immigration and expansion, allelic heterogeneity
might still be reduced by genetic drift before a more recent
expansion started, but the reduction is less strong than in the
older isolates. Furthermore, LD will exist over slightly longer
genomic regions. These populations have been useful for rare
Mendelian disease (29), but for common disorders the number
of founders might have been relatively high for some of these
populations, resulting in many different alleles present in the
population. This problem can be circumvented by using
extensive genealogical studies so that relatively shallow
pedigrees can be identified (31). This is especially feasible in
the population of Iceland, where the genealogy since the
original settlement is available. In this way, disease loci for
tremor, stroke and arteriosclerosis have been identified (32–35).
On the other hand, very young isolates (<20 generations),
such as the population of the Central Valley of Costa Rica
(CVCR) (36), Tristan da Cunha (37), Hutterites (12,38), small
population sub-isolates in the Netherlands (39) and French
Canada, have been identified with exponential population
growth in the last generations. In these populations, a very tight
founding bottleneck probably limits the number of mutations in
the current population. Long regions of LD have been detected
in these populations for bipolar illness (36,40) and type 1
diabetes (39). Although disease gene localization can benefit
from the use of isolated populations, there might be
disadvantages as well. Findings in isolated populations might
Figure 1. History of present-day linkage disequilibrium is shaped by recombination, gene conversion and consanguinity. If a mutation is present in the orange
segment, recombination events (A and D) degrade the region of LD around the mutation. Gene conversion degrades short-range LD (B). Increased consanguinity
(C) can result in enrichment of disease-associated alleles (E) but patterns of LD (F) can be complex as a result of converging haplotypes.
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not be valid in the general population, especially if in very old
isolated populations new mutations arise or if old mutations
remain while they became extinct in the general population. For
example, linkage findings for multiple sclerosis in Finland (41)
have not been replicated in other populations, but this is not
generally true for other diseases or in younger isolates, which
are still in many ways very similar to the general population
because of their recent separation. In addition, these findings
are very important for our understanding of the biological
process leading to disease.
THE DISTRIBUTION OF LD IN
THE HUMAN GENOME
In the recent literature, two central questions have been
discussed; how many SNPs would be needed for genome-wide
association studies and is there really a benefit using genetically
isolated populations? Central to this debate is the question of
how much linkage disequilibrium exists in different popula-
tions. LD is eroded by recombination and gene conversion
(Fig. 1) and influenced by the age and history of the mutation
and population size and structure. A number of groups have
studied the distribution of LD on the human genome. Kruglyak
(42) performed extensive computer simulation studies, which
provided a theoretical basis for our understanding of the
distribution of LD. Assuming an out-of-Africa human founding
population of 100 000 years ago, simulations were performed
taking genetic drift and different models of population history
into account, using bi-allelic markers equivalent to SNPs.
Under this scenario, a useful level of LD is not likely to extend
>3 kb in the general population. In addition, LD in isolated
populations would not be expected to differ much, except if the
founding bottleneck were very narrow (10–100 unrelated
individuals) or if the frequency of the variant were low
(<5%). In this scenario, 500 000 SNPs would be needed for
genome-wide association studies.
However, a series of ‘wet-lab’ genotyping studies did not fully
support these simulation studies (43–52). Although a large
variation in the extent of LD has been described, depending on
the chromosomal region studied, in general LD can be detected
over much larger genomic distances than expected in popula-
tions of northern European descent. There are large differences
in LD for different genomic regions, and the distribution of LD
can be described by blocks of extensive LD that are interspersed
by blocks showing little LD (49) (Fig. 2). The borders of these
blocks appear to be quite sharp and related to recombination
frequencies. There are some indications that specific sequence
content or motifs are important, but it is not known whether this
is a general mechanism (52–55). Thus, in the general population,
LD is more extensive than originally predicted, but the choice of
the density of a SNP map to catch a risk factor would have to take
the regional variation in LD into account. In order to be able to
make this choice, a genome-wide LD map should be con-
structed, and the first attempts are becoming available (56–58).
Preliminary comparisons of LD between populations with
different demographic histories have been made, and, indeed
(as could be expected) regions of LD in older populations tend
to be shorter in length than in younger populations. Most
regions of LD are shared between populations such as between
European and African populations, but also population-specific
LD exists for some regions, which has probably arisen after the
separation of both populations in history (59). In order to
obtain a useful LD map, LD should be measured across a dense
set of loci covering the entire genome in a range of populations.
LD IN ISOLATED POPULATIONS
In several of the studies mentioned above, samples from
populations considered as genetic isolates were included, and
not much difference in the length of LD with admixed
populations could be detected. This has been interpreted by
some that genetic isolates might not be more useful for gene
mapping than the general population. However, much of this
debate is clouded by the fact that some of these statements are
imprecise. For example, in several studies on LD, samples from
the population of Sardinia have been used. Sardinia is regarded
as a genetically isolated population by several authors, but this
is not generally true for the whole population of Sardinia. On
many coastal areas, there have been influences from outside
populations (60,61). Unless authors clearly give evidence that
the samples are from real genetically isolated populations, these
data cannot be properly interpreted. In line with this, one
should realize that Iceland is not a simple homogeneous genetic
isolate, but instead has been founded by a mix of populations
(62–64). The Norse founders were mostly male and the
founding females were mostly of Gaelic origin. In addition, in
Finland, two founding populations exist, one of which is much
older (2000 years) than the other (500 years) (29).
In contrast to the findings above, several studies on very
young isolates (<20 generations) show very promising results
by detecting LD over long distances (>1 cM), such as in the
populations of the Central Valley of Costa Rica and Palau
(56,57) and Dutch sub-isolates (manuscript in preparation). It
should further be noted that the extent of background LD in
the population under study is not the most important measure
to consider, but the difference of LD around risk factors
in patients compared to this background LD in these
populations (65).
FROM GENE MAPPING TO GENE FINDING
Developing methodology to successfully map genetic risk
factors for complex disorders is only a first step towards the
identification of these risk factors. The use of very young
isolates, with extended LD, should make it relatively easy to
find a locus with a limited number of markers. The ease of
finding LD, however, has a downside as well, because in order
to reduce the region of interest large population samples are
needed. The second step towards the identification of the
biologically relevant mutation will therefore be more difficult
in younger isolates compared with older isolates, in which on
average shorter LD exists. In older isolates, more markers
would be needed for the initial screen, but the identified region
can be expected to be shorter than for younger isolates. An
attractive strategy would be to carry out the initial screen in a
young isolate followed by fine mapping in an older isolate or
even in the general population. Therefore it would be useful to
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collect additional samples from other (isolated) populations or
to organize repositories of population samples.
Even though, in this way, the number of candidate genes can
be reduced considerably, the problem of identifying the
biologically relevant mutation remains. There is a need to
screen for variants in the whole region that is in LD, since not
all SNPs are known. It is often estimated that an SNP exists in 1
in 1000 bp, but some studies reached a much higher number
of variants (1 in 200 bp) by re-sequencing larger number of
individuals, which means that many SNPs remain to be
detected (66). An alternative is to only test SNPs within
functional candidate genes. However, the function of most
genes is not known, and their selection is therefore not (yet)
very specific. Once all SNPs have been identified and tested,
several will demonstrate evidence for association. The problem
will be how to separate the biological relevant mutations from
harmless SNPs that are in complete LD. Testing the biological
effect of each of these SNPs is a possible solution. However,
this approach is not feasible if extended regions of LD exist: an
example is the region around the microtubule-associated
protein tau (MAPT) gene on chromosome 17q21 (Fig. 2).
Mutations in MAPT are associated with frontotemporal
dementia with parkinsonism linked to chromosome 17
(FTDP-17) (67–69). In addition there is strong evidence that
MAPT harbors a risk factor for other neurodegenerative
disorders such as progressive supranuclear palsy, corticobasal
degeneration and even late-onset Parkinson’s disease (5).
However, the detection of the biologically relevant mutation
has so far puzzled scientists, because the region shows
extensive LD for a number of SNPs spanning the whole
MAPT gene (>100 kb). In populations of European descent,
only two major haplotypes exist for the gene. A possible
solution might come from testing LD in additional populations
with a different ethnicity. It is currently not known how much
difference in LD exists between populations, but there are
indications that population-specific LD exists (59), again
demonstrating the importance of population-specific LD maps.
MUTATIONS IN DISTANT REGULATORY
ELEMENTS
Since mutations involved in complex disorders are often not
directly causal, they can be expected to have mild biochemical
effects. Mutations can be located within coding regions of
genes and affect the function of the protein, or can have an
effect on the function of the protein by changing alternative
splicing or secondary structure, stability, translation or
localization of the mRNA. To test such effects, functional
assays can be designed. Although this is already a major task,
in addition mutations can be located outside the coding region
of the gene in elements that control timing, location and/or
level of gene expression. Several studies have demonstrated
that by using comparative genomics and expression data,
conserved sequences can be identified in the genome that might
act as regulatory elements (70–72). However, we do not know
Figure 2. Top: Linkage disequilibrium (LD) in the human genome (double line) is organized in a block-like structure. SNPs are indicated by vertical lines. Regions
of high LD (boxes) are interspersed with regions of low LD (49). The strength of long-range LD is inversely correlated with recombination frequencies (82). Short-
range LD is mainly degraded by gene conversion (83). Bottom: Genomic organization of the microtubule-associated protein tau (MAPT) gene. Exons are indicated
by colored boxes. A large number of SNP variants (indicated by arrows) show strong LD over >100 kb. Early association studies demonstrated a strong association
of a polymorphic short tandem repeat allele within intron 9 (A0) and several neurodegenerative disorders. This association now extends over the whole gene,
including the promoter region (5).
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how far such regulatory sequences extend. Most studies
investigate a limited amount of sequence around a gene, but
is this really sufficient? For most cases, it probably will be, but
there is increasing evidence for the existence of long-ranging
cis-acting elements in the genome. One example is adult-type
hypolactasia, or lactose intolerance, an autosomal recessive
disease with a physiological decline in the activity of the
lactase–phlorizin hydrolase (LPH) (73). Families linked to the
gene encoding LPH (the LCT gene) showed no mutations
within the gene, but the associated haplotype spanning the LCT
gene showed differences in transcript levels of non-persistence,
suggesting a cis-acting allele. Subsequent LD and haplotype
analysis in Finnish families demonstrated that the mutation had
to be located within a 47 kb interval around the gene. Two point
mutations, a C/T variant 14 kb and a G/A change 22 kb
upstream of the LCT gene, were identified. These variants were
also associated in distantly related populations, indicating that
they are very old. This example is certainly not unique or a
worst-case scenario. Long-range cis-acting regulatory elements
have been described for the Sonic hedgehog (Shh) gene, which
is associated with polydactyly and holoprosencephaly.
Chromosomal rearrangements >250 kb upstream of the Shh
gene have been identified in patients with holoprosencephaly
(74). In addition, in families with polydactyly, cis-acting limb-
specific regulatory sequences for the Shh gene are located at
least 800 kb upstream of the gene and embedded in an intron of
another gene (75) (Fig. 3). Additional examples such as SOX9
(76), PAX6 (77) and b-globin (78) demonstrate that this is not
an exceptional phenomenon. The examples above have only
been found because there was a strong functional candidate
gene and because a relatively small region of LD could be
determined owing to the genetic isolation of the population
under study and the availability of genealogical data. It might
be more difficult for less obvious factors. In the case of
polydactyly, recombination events excluded the responsible
gene by 800 kb (79). This demonstrates that the selection of
candidate genes should not only be based on function and
location within the borders of the critical region, but also
include extensive in silico genome analysis of a more broadly
defined region.
A PLEA TO ASCERTAIN GENETICALLY
ISOLATED POPULATIONS
Some of the promises of the use of isolated populations are
beginning to be apparent, but many questions remain. Since
Figure 3. Top: Genomic organization around the pre-axial polydactyly (PPD) critical region (79). Colored boxes indicate transcripts. Arrows indicate direction of
transcription. LMBR1 contains a cis-acting limb-specific transcriptional repressor for the Sonic hedgehog (Shh) gene (75). Bottom: Intron/exon structure of
LMBR1. The deletion reported for acheiropodia (84), the translocation t(5,7)(q11,q36) and the Sasquatsh transgene integration leading to abolishment of limb-
specific Shh repression are indicated (75).
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each disease has its own characteristics, it has been suggested
to improve study design by adapting the study population
choice to the specific research question under study (11,80).
This would imply that there is a need to investigate a large
number of different genetically isolated populations, each with
its own demographic history and health characteristics. Where
are these populations to be found? This seems not to be an easy
task, but it should be realized that even within very densely
populated countries such as the Netherlands, genetically
isolated subpopulations have been identified based on religious,
behavioral or socio-economic isolation. If isolated populations
hold the key to finding genes for complex disorders that affect
maybe 60% of our population (81), the timely collection of
samples from genetically isolated populations is crucial,
because the increasing mobility of people from all over the
world will lead to the disappearance of many of these
populations in the nearby future.
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